Previous close | 15.93 |
Open | 15.86 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 900 |
Day's range | 15.61 - 15.89 |
52-week range | 13.16 - 17.85 |
Volume | |
Avg. volume | 581,995 |
Market cap | 5.567B |
Beta (5Y monthly) | 0.46 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.29 |
Earnings date | 31 July 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 27.22 |
From what we can see, insiders were net buyers in Bausch + Lomb Corporation's ( NYSE:BLCO ) during the past 12 months...
The transaction was filed with the SEC and indicates a strong signal of confidence from the insider. Following this acquisition, the insider now owns 627,419 shares of Bausch & Lomb Corp. Bausch & Lomb Corp is primarily engaged in the development, manufacture, and marketing of a range of pharmaceutical, medical device, and over-the-counter products, particularly in eye health.
VAUGHAN, Ontario, July 31, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results.